Table 1 Major characteristics of the included studies
From: Compared efficacy of clopidogrel and ticagrelor in treating acute coronary syndrome: a meta-analysis
Study | Publication year | Study design | No. Patients | Drug Dose | Follow-up, mo | Clinical Outcome | ||
|---|---|---|---|---|---|---|---|---|
Ticagrelor | Clopidogrel | Ticagrelor, mg.q.d | Clopidogrel, mg.q.d | |||||
Cannon | 2007 | RCT | 6732 | 6676 | 90 mg.bid | LD: 300 MD: 75 | 3 | 1、2、3、4 |
Lars Wallentin | 2009 | RCT | 9333 | 9291 | LD: 180 mg.bid MD: 90 mg.bid | LD: 300–600 MD: 75 | 12 | 1、2、3、4 |
Cannon | 2010 | RCT | 663 | 327 | LD: 180 mg.bid MD: 90 mg.bid | LD: 300 MD: 75 | 12 | 1、2、3 |
Laurent Bonello | 2014 | RCT | 30 | 30 | LD: 180 mg.bid MD: 90 mg.bid | LD: 600 MD: 75 | N | 4 |
Y. Hiasa | 2014 | RCT | 93 | 46 | 90/45 mg.bid | 75 | 3 | 3 |
Shinya Goto | 2015 | RCT | 401 | 400 | LD: 180 mg.bid MD: 90 mg.bid | LD: 300 MD: 75 | 12 | 1、2、3 |
Huidong Wang | 2016 | RCT | 100 | 100 | LD: 180 mg.bid MD: 90 mg.bid | LD: 300 MD: 75 | 12 | 1、2、3 |
Ran Xiong | 2015 | RCT | 112 | 112 | LD: 180 mg.bid MD: 90 mg.bid | LD: 600 MD: 150 | 12 | 1 |
I-Chih Chen | 2016 | PSM | 224 | 224 | / | / | 12 | 1、2、3、4 |
Cheng-Han Lee | 2018 | PSM | 2389 | 19,112 | LD: 180 mg.bid MD: 90 mg.bid | LD: 300–600 MD: 75 | 18 | 1、2、3 |